Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT01436968
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
- NCT01436968 ↗
- Active, not recruiting
- Candel Therapeutics, Inc.
- Focused
We haven't built an HCP commentary report on NCT01436968 (aglatimagene besadenovec (CAN-2409) in localized prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT01436968 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Aglatimagene besadenovec + valacyclovir; Placebo + valacyclovir
- Arms
- ProstAtak® · Experimental
- Control · Placebo comparator
- Enrollment
- 711 (estimated)
- Primary outcomes
- Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.
- Sponsor
- Candel Therapeutics, Inc.
- Start
- Sep 2011
- Primary completion
- Aug 2024
- Results posted
- No
- Registry record
- NCT01436968 · updated Oct 2, 2026
Publications
linked from the registry- DeWeese TL, Manzanera A, Sylvester J, Wheeler T, Schroeder T, Gejerman G, Chesnut G, Facelle TM, Garzotto MG, Pieczonka C, Gandhi NM, Sukin S, Liss MA, Tutrone R, Mehlhaff B, Savage SJ, Goody M, Vogt J, Rao S, Polanco MLS, Barone F, Nichols WG, Tak PP; PrTK03 study team. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2026 Jun;27(6):673-685. doi: 10.1016/S1470-2045(26)00071-9. PubMed 42225101